Olanzapine Helps Compliance in Schizophrenia

Article excerpt

PRAGUE, CZECH REPUBLIC -- Patients receiving olanzapine are achieving greater symptom control and longer treatment compliance than those on other leading atypical antipsychotic medications, researchers reported from 6-month results of the ongoing international Schizophrenia Outpatient Health Outcomes study.

But the effectiveness of antipsychotics on the clinical status, tolerability, and quality of life of schizophrenia patients in common clinical practice is not yet well documented, Dr. Dieter Naber, who is professor of psychiatry at the University of Hamburg (Germany), said at the annual congress of the European College of Neuropsychopharmacology. That's what makes the Schizophrenia Outpatient Health Outcomes (SOHO) study so valuable. [It] "provides us with detailed naturalistic data with regard to clinical status and quality of life of patients treated for schizophrenia with olanzapine and other antipsychotics throughout Europe," Dr. Naber said.

SOHO involves more than 17,750 patients in 37 countries. The investigators are collecting data from physicians' offices over 3 years. At the start of the study, at 3 and 6 months, the investigators collected data measuring treatment effectiveness (Clinical Global Impressions-Severity of Illness, overall, positive, negative, cognitive, and depressive domains), safety (incidence of extrapyramidal symptoms or tardive dyskinesia), side effects (sexual dysfunction and weight gain), and functional status (social and work functioning).

They established three treatment groups: olanzapine (Zyprexa); risperidone (Risperdal); and a category called "other antipsychotics" (nonolanzapine, including risperidone).

At 6 months, the olanzapine group showed the greatest improvement in positive symptoms (delusions and hallucinations), negative symptoms (diminished emotion, lack of interest), as well as cognitive and social functioning symptoms, compared with subjects on risperidone, quetiapine (Seroquel), and oral typical and depot typical antipsychotics. …


An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.